VIRX vs. SPRB, DARE, ACXP, IPA, FBIO, THTX, NRXP, BCTX, ENLV, and MRKR
Should you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include Spruce Biosciences (SPRB), Daré Bioscience (DARE), Acurx Pharmaceuticals (ACXP), ImmunoPrecise Antibodies (IPA), Fortress Biotech (FBIO), Theratechnologies (THTX), NRx Pharmaceuticals (NRXP), BriaCell Therapeutics (BCTX), Enlivex Therapeutics (ENLV), and Marker Therapeutics (MRKR). These companies are all part of the "pharmaceutical preparations" industry.
Spruce Biosciences (NASDAQ:SPRB) and Viracta Therapeutics (NASDAQ:VIRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings, dividends and community ranking.
91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 31.4% of Viracta Therapeutics shares are held by institutional investors. 9.1% of Spruce Biosciences shares are held by insiders. Comparatively, 7.4% of Viracta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Spruce Biosciences presently has a consensus price target of $5.67, suggesting a potential upside of 608.33%. Viracta Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 733.33%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Viracta Therapeutics is more favorable than Spruce Biosciences.
Spruce Biosciences has higher revenue and earnings than Viracta Therapeutics. Spruce Biosciences is trading at a lower price-to-earnings ratio than Viracta Therapeutics, indicating that it is currently the more affordable of the two stocks.
Spruce Biosciences has a beta of 2.5, meaning that its stock price is 150% more volatile than the S&P 500. Comparatively, Viracta Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.
Spruce Biosciences received 12 more outperform votes than Viracta Therapeutics when rated by MarketBeat users. However, 72.22% of users gave Viracta Therapeutics an outperform vote while only 63.33% of users gave Spruce Biosciences an outperform vote.
Viracta Therapeutics has a net margin of 0.00% compared to Viracta Therapeutics' net margin of -461.67%. Viracta Therapeutics' return on equity of -54.27% beat Spruce Biosciences' return on equity.
In the previous week, Spruce Biosciences had 2 more articles in the media than Viracta Therapeutics. MarketBeat recorded 9 mentions for Spruce Biosciences and 7 mentions for Viracta Therapeutics. Spruce Biosciences' average media sentiment score of 0.89 beat Viracta Therapeutics' score of 0.41 indicating that Viracta Therapeutics is being referred to more favorably in the news media.
Summary
Spruce Biosciences beats Viracta Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Viracta Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VIRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viracta Therapeutics Competitors List
Related Companies and Tools
